- Home
- CRF vs QURE Comparison
CRF vs QURE Comparison
Compare CRF & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRF | QURE |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 1997 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CRF | QURE |
|---|---|---|
| Price | $7.18 | $18.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $44.92 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | N/A | $126.12 |
| Revenue Next Year | N/A | $200.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.43 | $8.73 |
| 52 Week High | $8.25 | $71.50 |
Technical Indicators
Market Signals| Indicator | CRF | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 54.81 |
| Support Level | $6.98 | $13.47 |
| Resistance Level | $8.04 | $18.37 |
| Average True Range (ATR) | 0.12 | 1.43 |
| MACD | 0.04 | 0.30 |
| Stochastic Oscillator | 67.19 | 80.23 |
Price Performance
Historical ComparisonAbout CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology, Health Care, Financials, Communication Services, Consumer Discretionary, Industrials, Exchange-Traded Funds, Utilities, Energy, Real Estate, and others.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.